Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children's Cancer Group

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 24

PMID 35747795

Authors

Yong Zhuang

Kefei Wu

Xiaofan Zhu

Jiaoyang Cai

ShaoYan Hu

Ju Gao

Hua Jiang

Xiaowen Zhai

Xin Tian

Yongjun Fang

Runming Jin

Qun Hu

Hui Jiang

Ningling Wang

Lirong Sun

Wing Kwan Leung

Minghua Yang

Kaili Pan

Xuedong Wu

Changda Liang

Shuhong Shen

Jie Yu

Xiuli Ju

Affiliations

Soon will be listed here.

Abstract

Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=10115, identifier ChiCTR-IPR-14005706.

Citing Articles

[Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].

Zhu X Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(4):344-349.

PMID: 37073837 PMC: 10120335. DOI: 10.7499/j.issn.1008-8830.2211041.

Prognostic significance of steroid response in pediatric acute lymphoblastic leukemia: The CCCG-ALL-2015 study.

Chu J, Cai H, Cai J, Bian X, Cheng Y, Guan X Front Oncol. 2023; 12:1062065.

PMID: 36624786 PMC: 9824631. DOI: 10.3389/fonc.2022.1062065.

References

Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A . Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014; 99(7):1220-7. PMC: 4077084. DOI: 10.3324/haematol.2014.103507. View

Shen S, Chen X, Cai J, Yu J, Gao J, Hu S . Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020; 6(3):358-366. PMC: 6990720. DOI: 10.1001/jamaoncol.2019.5868. View

Gaynon P, Trigg M, Heerema N, Sensel M, Sather H, Hammond G . Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2001; 14(12):2223-33. DOI: 10.1038/sj.leu.2401939. View

Hunger S, Mullighan C . Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015; 373(16):1541-52. DOI: 10.1056/NEJMra1400972. View

Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J . Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia. 2000; 14(3):356-63. DOI: 10.1038/sj.leu.2401704. View

Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W, Henze G . Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2001; 14(12):2205-22. DOI: 10.1038/sj.leu.2401973. View

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Moricke A, Locatelli F . Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2017; 36(3):244-253. DOI: 10.1200/JCO.2017.74.4946. View

OConnor D, Bate J, Wade R, Clack R, Dhir S, Hough R . Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014; 124(7):1056-61. DOI: 10.1182/blood-2014-03-560847. View

Matloub Y, Bostrom B, Hunger S, Stork L, Angiolillo A, Sather H . Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(2):243-51. PMC: 3138679. DOI: 10.1182/blood-2010-12-322909. View

10.

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

11.

Pedrosa F, Coustan-Smith E, Zhou Y, Cheng C, Pedrosa A, Lins M . Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study. Blood. 2020; 135(17):1458-1466. PMC: 7180080. DOI: 10.1182/blood.2019004215. View

12.

Sundaresh A, Williams O . Mechanism of ETV6-RUNX1 Leukemia. Adv Exp Med Biol. 2017; 962:201-216. DOI: 10.1007/978-981-10-3233-2_13. View

13.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C . Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8):809-18. DOI: 10.1016/S1470-2045(14)70243-8. View

14.

Matloub Y, Lindemulder S, Gaynon P, Sather H, La M, Broxson E . Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic.... Blood. 2006; 108(4):1165-73. PMC: 1895867. DOI: 10.1182/blood-2005-12-011809. View

15.

Pui C, Dodge R, Look A, George S, Rivera G, Abromowitch M . Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol. 1991; 9(8):1341-7. DOI: 10.1200/JCO.1991.9.8.1341. View

16.

Li X, Li J, Luo X, Wu X, Sun X, Xu H . Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. BMC Cancer. 2021; 21(1):59. PMC: 7805214. DOI: 10.1186/s12885-020-07752-x. View

17.

Pui C, Pei D, Raimondi S, Coustan-Smith E, Jeha S, Cheng C . Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia. 2016; 31(2):333-339. PMC: 5288281. DOI: 10.1038/leu.2016.234. View

18.

Jeha S, Pei D, Choi J, Cheng C, Sandlund J, Coustan-Smith E . Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019; 37(35):3377-3391. PMC: 7351342. DOI: 10.1200/JCO.19.01692. View

19.

Pui C, Campana D, Pei D, Bowman W, Sandlund J, Kaste S . Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360(26):2730-41. PMC: 2754320. DOI: 10.1056/NEJMoa0900386. View

20.

Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M . Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2017; 32(3):606-615. DOI: 10.1038/leu.2017.265. View